Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma; HKEX: 02659) has filed its Monthly Return for the period ended 30 September 2026, detailing a further contraction of its H-share float through on-market repurchases.

Total authorised capital remained unchanged at 325.98 million ordinary shares with a par value of RMB 0.20, equivalent to RMB 65.20 million. The structure is split between 154.33 million H shares listed in Hong Kong and 171.65 million unlisted domestic shares.

During 1–8 September, the company executed six repurchase transactions, buying back 873,700 H shares at prices ranging from HK$15.98 to HK$16.73. The repurchases, approved at the 26 May 2026 general meeting, reduced H shares in issue (excluding treasury stock) to 151.54 million—down 0.57% versus end-August—and increased treasury shares to 2.79 million, representing around 1.81% of the class.

Based on disclosed per-share prices and volumes, the aggregate consideration for the September buy-backs is calculated at approximately HK$14.34 million, translating to an average cost of about HK$16.41 per share.

Domestic share capital stood unchanged at 171.65 million shares. Consequently, total issued share capital (including treasury shares) was stable at 325.98 million shares. Bao Pharma confirmed that, as at 30 September 2026, its public float satisfies the Hong Kong Stock Exchange’s minimum 25% requirement and that all repurchases complied with applicable listing and regulatory provisions.